NASPCC Symposium on Immuno-Oncology in Prostate Cancer: Current and Future Trends
June 24, 2021
10:00 am – 2:30 pm (Pacific)
1:00 pm – 5:30 pm (Eastern)

10:00 am – 10:05 am  Introduction
Merel Nissenberg, Esq., President, NASPCC

10:05 am – 10:15 am  Introductory Remarks
Saul Priceman, PhD
City of Hope Medical Center

Session One

10:15 am – 10:35 am  Redirecting T-Cells for Prostate Cancer Immunotherapy
Lawrence Fong, MD
University of California, San Francisco

10:40 am – 11:00 am  CAR-T Development in Sub-Types of Prostate Cancer: How Mechanistic Biology Impacts Future Therapies
John Lee, MD, PhD
Fred Hutchinson Cancer Center

11:05 am – 11:25 am  Chimeric Antigen Receptor T-Cell Therapies for Advanced Prostate Cancer: Clinical Trials (and Tribulations)
Vivek Narayen, MD, MS
University of Pennsylvania

11:30 am – 11:50 am  Advancing CAR-T Cells for Prostate Cancer
Saul Priceman, PhD
City of Hope Medical Center

11:50 am – 12:10 pm  Panel Discussion

12:10 pm – 12:25 pm  Break
Session Two

12:30 pm – 12:50 pm
Upcoming Clinical Trial of AMG 757, a DLL3/CD3 BiTE, in Neuroendocrine Prostate Cancer
Rahul Aggarwal, MD
University of California, San Francisco

12:55 pm – 1:15 pm
Anti-CTLA-4-Therapy in Prostate Cancer
Sumit Subudhi, MD, PhD
UT MD Anderson Cancer Center

1:20 pm – 1:40 pm
The QuEST for an Effective Immunotherapy for Prostate Cancer
James Gulley, MD, PhD
National Institutes of Health (NIH)

1:45 pm – 2:05 pm
Allogenic Approaches to Cell Therapy for Tumors of Various Sorts
Charles Drake, MD, PhD
New York-Presbyterian/Columbia

2:10 pm – 2:30 pm
Panel Discussion

2:30 pm
Closing Remarks